{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:04:29Z","timestamp":1777637069495,"version":"3.51.4"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG018440"],"award-info":[{"award-number":["AG018440"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG073979"],"award-info":[{"award-number":["AG073979"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS047101"],"award-info":[{"award-number":["NS047101"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Multiple System Atrophy (MSA) is a rare, sporadic, age-related synucleinopathy characterized by Parkinson-like motor symptoms and ataxia. There is no therapy for MSA other than symptomatic treatment. MSA is characterized pathologically by glial cytoplasmic inclusions (GCI) of \u03b1-synuclein (\u03b1Syn) occurring in oligodendrocytes leading to loss of myelination in the brain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We recently utilized a peptide-mediated delivery method to systemically transport an anti-sense oligonucleotide (ASO) targeted to \u03b1Syn in a mouse model of MSA. We hypothesized that systemic delivery of \u03b1Syn ASO by peptide mediated delivery to a mouse model of MSA would reduce the \u03b1Syn accumulation in oligodendrocytes and reduce the overt pathology associated with MSA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Following monthly treatments of the \u03b1Syn ASO, we found increased myelination in the corpus callosum, cerebellum and brainstem. We also observed increased numbers of oligodendrocytes and reduced gliosis; however, we did not detect changes in overall \u03b1Syn in the areas of the brain we examined. Upon further analysis, we determined the peptide-mediated delivery of \u03b1Syn ASO was not taken up by oligodendrocytes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Thus, we have successfully alleviated some of the pathology associated with MSA in a mouse model; however, without direct delivery to oligodendrocytes, other approaches may need to supplement this therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnagi.2026.1807721","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:01:26Z","timestamp":1777442486000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic delivery of anti-sense oligonucleotide targeting \u03b1-synuclein for treatment in a mouse model of multiple system atrophy"],"prefix":"10.3389","volume":"18","author":[{"given":"Brian","family":"Spencer","sequence":"first","affiliation":[{"name":"Department of Physiology and Neuroscience, Epstein Family Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California","place":["San Diego, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bao","family":"Quach","sequence":"additional","affiliation":[{"name":"Department of Physiology and Neuroscience, Epstein Family Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California","place":["San Diego, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Salehi","sequence":"additional","affiliation":[{"name":"Department of Physiology and Neuroscience, Epstein Family Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California","place":["San Diego, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Rissman","sequence":"additional","affiliation":[{"name":"Department of Physiology and Neuroscience, Epstein Family Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California","place":["San Diego, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1101\/2025.05.01.651722","article-title":"Anti-sense oligonucleotide as a therapeutic for synucleinopathies: pharmacokinetic, safety and efficacy evaluation","author":"Ahammad","year":"","journal-title":"bioRxiv"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e70117","DOI":"10.1002\/trc2.70117","article-title":"A splice-switching antisense oligonucleotide targeting APP reduces accumulation of alpha-synuclein in a mouse model of Parkinson's disease","volume":"11","author":"Ahammad","year":"","journal-title":"Alzheimers Dement."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1365-2990.2011.01234.x","article-title":"The neuropathology, pathophysiology and genetics of multiple system atrophy","volume":"38","author":"Ahmed","year":"2012","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.3390\/ijms25094809","article-title":"Antisense oligonucleotides (ASOs) in motor neuron diseases: a road to cure in light and shade","volume":"25","author":"Cantara","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"13010","DOI":"10.1073\/pnas.0903691106","article-title":"Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein","volume":"106","author":"Desplats","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"42984","DOI":"10.1038\/srep42984","article-title":"\u03b1-synuclein transfer through tunneling nanotubes occurs in SH-SY5Y cells and primary brain pericytes from Parkinson's disease patients","volume":"7","author":"Dieriks","year":"2017","journal-title":"Sci. Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00401-016-1572-y","article-title":"\u03b1-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy","volume":"132","author":"Ettle","year":"2016","journal-title":"Acta Neuropathol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/bpa.12678","article-title":"Oligodendroglial alpha-synucleinopathy-driven neuroinflammation in multiple system atrophy","volume":"29","author":"Hoffmann","year":"2019","journal-title":"Brain Pathol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/embo-reports\/kvf109","article-title":"Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes","volume":"3","author":"Kahle","year":"2002","journal-title":"EMBO Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e503","DOI":"10.1097\/RLU.0000000000005347","article-title":"Clinical application of 18 F-THK5351 PET to image ongoing astrogliosis in MSA-P and MSA-C","volume":"49","author":"Kondo","year":"2024","journal-title":"Clin. Nucl. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","article-title":"Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders","volume":"4","author":"Lauffer","year":"2024","journal-title":"Commun. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"106285","DOI":"10.1016\/j.nbd.2023.106285","article-title":"Novel systemic delivery of a peptide-conjugated antisense oligonucleotide to reduce alpha-synuclein in a mouse model of Alzheimer's disease","volume":"186","author":"Leitao","year":"","journal-title":"Neurobiol. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3233\/JAD-230232","article-title":"Hippocampal Reduction of alpha-Synuclein via RNA Interference Improves Neuropathology in Alzheimer's Disease Mice","volume":"95","author":"Leitao","year":"","journal-title":"J. Alzheimers. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/14728214.2024.2333420","article-title":"Evaluating emerging drugs in phase II & III for the treatment of amyotrophic lateral sclerosis","volume":"29","author":"Li","year":"2024","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"B15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/17460441.2023.2200245","article-title":"The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies","volume":"18","author":"Lozupone","year":"2023","journal-title":"Expert Opin. Drug Discov."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1016\/j.neurobiolaging.2014.02.028","article-title":"\u03b1-Synuclein impairs oligodendrocyte progenitor maturation in multiple system atrophy","volume":"35","author":"May","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"B17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40478-021-01166-x","article-title":"Human alpha-synuclein overexpressing MBP29 mice mimic functional and structural hallmarks of the cerebellar subtype of multiple system atrophy","volume":"9","author":"Meszaros","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"B18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40478-017-0445-5","article-title":"Brain-derived exosomes from dementia with Lewy bodies propagate alpha-synuclein pathology","volume":"5","author":"Ngolab","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"B19","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s00401-003-0811-1","article-title":"Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy","volume":"107","author":"Nishie","year":"2004","journal-title":"Acta Neuropathol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13024-022-00579-z","article-title":"Multiple system atrophy: alpha-Synuclein strains at the neuron-oligodendrocyte crossroad","volume":"17","author":"Reddy","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.bbalip.2015.02.010","article-title":"Cholesterol in myelin biogenesis and hypomyelinating disorders","volume":"1851","author":"Saher","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"B22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s12272-024-01499-w","article-title":"Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington's disease","volume":"47","author":"Shafie","year":"2024","journal-title":"Arch. Pharm. Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"10689","DOI":"10.1523\/JNEUROSCI.3527-05.2005","article-title":"Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy","volume":"25","author":"Shults","year":"2005","journal-title":"J. Neurosci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.nbd.2019.03.001","article-title":"Systemic peptide mediated delivery of an siRNA targeting alpha-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease","volume":"127","author":"Spencer","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13024-015-0043-6","article-title":"A brain-targeted, modified neurosin (kallikrein-6) reduces alpha-synuclein accumulation in a mouse model of multiple system atrophy","volume":"10","author":"Spencer","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"B26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0304-3940(98)00504-7","article-title":"Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies","volume":"251","author":"Spillantini","year":"1998","journal-title":"Neurosci. Lett."},{"key":"B27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.expneurol.2012.01.008","article-title":"Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of alpha-synucleinopathy","volume":"234","author":"Ubhi","year":"2012","journal-title":"Exp. Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"6236","DOI":"10.1523\/JNEUROSCI.0567-10.2010","article-title":"Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors","volume":"30","author":"Ubhi","year":"2010","journal-title":"J. Neurosci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40478-016-0409-1","article-title":"Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy","volume":"5","author":"Valera","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"B30","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0304-3940(98)00407-8","article-title":"Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy","volume":"249","author":"Wakabayashi","year":"1998","journal-title":"Neurosci. Lett."},{"key":"B31","doi-asserted-by":"publisher","first-page":"a024588","DOI":"10.1101\/cshperspect.a024588","article-title":"\u03b1-Synuclein: multiple system atrophy prions","volume":"8","author":"Woerman","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e128114","DOI":"10.1172\/JCI128114","article-title":"Aberrant oligodendroglial LDL receptor orchestrates demyelination in chronic cerebral ischemia","volume":"131","author":"Xie","year":"2021","journal-title":"J. Clin. Invest."},{"key":"B33","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.neuron.2005.01.032","article-title":"Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration","volume":"45","author":"Yazawa","year":"2005","journal-title":"Neuron"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1002\/dvdy.21283","article-title":"Selective expression of LDLR and VLDLR in myelinating oligodendrocytes","volume":"236","author":"Zhao","year":"2007","journal-title":"Dev. Dyn."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1807721\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:01:27Z","timestamp":1777442487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1807721\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":34,"alternative-id":["10.3389\/fnagi.2026.1807721"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2026.1807721","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"article-number":"1807721"}}